Abstract
Background
Epidemiological studies of interstitial lung disease (ILD) are limited by small numbers and tertiary care bias. Investigators have leveraged the widespread use of electronic health records (EHRs) to overcome these limitations, but struggle to extract patient-level, longitudinal clinical data needed to address many important research questions. We hypothesized that we could automate longitudinal ILD cohort development using the EHR of a large, community-based healthcare system.
Study design and methods
We applied a previously validated algorithm to the EHR of a community-based healthcare system to identify ILD cases between 2012–2020. We then extracted disease-specific characteristics and outcomes using fully automated data-extraction algorithms and natural language processing of selected free-text.
Results
We identified a community cohort of 5,399 ILD patients (prevalence = 118 per 100,000). Pulmonary function tests (71%) and serologies (54%) were commonly used in the diagnostic evaluation, whereas lung biopsy was rare (5%). IPF was the most common ILD diagnosis (n = 972, 18%). Prednisone was the most commonly prescribed medication (911, 17%). Nintedanib and pirfenidone were rarely prescribed (n = 305, 5%). ILD patients were high-utilizers of inpatient (40%/year hospitalized) and outpatient care (80%/year with pulmonary visit), with sustained utilization throughout the post-diagnosis study period.
Discussion
We demonstrated the feasibility of robustly characterizing a variety of patient-level utilization and health services outcomes in a community-based EHR cohort. This represents a substantial methodological improvement by alleviating traditional constraints on the accuracy and clinical resolution of such ILD cohorts; we believe this approach will make community-based ILD research more efficient, effective, and scalable.
Funder
Genentech
Pulmonary Fibrosis Foundation
Publisher
Public Library of Science (PLoS)
Reference38 articles.
1. Update in Interstitial Lung Disease 2019;SB Montesi;Am J Respir Crit Care Med,2020
2. Interstitial lung disease;KM Antoniou;Eur Respir Rev,2014
3. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older.;HR Collard;Ann Am Thorac Soc,2015
4. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.;N Wu;J Med Econ,2015
5. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.;MT Durheim;Respirology,2021